1446018-07-0

Basic information

• Product Name: N,5-bis(4-methoxybenzyl)-4-(4-methoxyphenyl)thiazol-2-amine
• Synonyms: N,5-bis(4-methoxybenzyl)-4-(4-methoxyphenyl)thiazol-2-amine
• CAS NO: 1446018-07-0
• Molecular Weight: 446.57
• Mol File: 1446018-07-0.mol
• Article Data: 1

Chemical Properties

• CAS DataBase Reference: N,5-bis(4-methoxybenzyl)-4-(4-methoxyphenyl)thiazol-2-amine(CAS DataBase Reference)
• NIST Chemistry Reference: N,5-bis(4-methoxybenzyl)-4-(4-methoxyphenyl)thiazol-2-amine(1446018-07-0)
• EPA Substance Registry System: N,5-bis(4-methoxybenzyl)-4-(4-methoxyphenyl)thiazol-2-amine(1446018-07-0)

Safety Data

• Hazardous Substances Data: 1446018-07-0(Hazardous Substances Data)

Upstream product

• 106511-67-5 5-(4-methoxybenzyl)-4-(4-methoxyphenyl)thiazol-2-amine 
• 106511-72-2 2-Bromo-1,3-bis-(4-methoxy-phenyl)-propan-1-one 
• 20615-47-8 1,3-di(4-methoxyphenyl)propan-1-one 
• 123-11-5 4-methoxy-benzaldehyde 
• 100-06-1 1-(4-methoxyphenyl)ethanone 
• 41564-67-4 (E)-1,3-bis(4-methoxyphenyl)-2-propene-1-one 

Relevant articles and documents

2,4,5-Trisubstituted thiazole derivatives: A novel and potent class of non-nucleoside inhibitors of wild type and mutant HIV-1 reverse transcriptase

Novel 2,4,5-trisubstituted thiazole derivatives (TSTs) were designed and synthesized as HIV-1 non-nucleoside reverse transcriptase inhibitors (NNRTIs). Among the thirty-eight synthesized target compounds, thirty TSTs showed potent inhibition against HIV-1 replication in wild type HIV-1 at submicromolar concentrations (from 0.046 to 9.59 μM). Compounds 21, 23 and 24 were also tested on seven NNRTI-resistant HIV-1 strains, and all exhibited inhibitory effects with fold changes in IC50 ranging from 2.6 to 111, which were better than those of nevirapine (15.6-fold-371-fold). Docking simulations of compound 24 revealed a reasonable mechanism for the binding mode, and three-dimensional quantitative structure activity relationship (3-DQSAR) studies on this novel series of TST further elucidated the structure-activity relationship (SAR). The results suggested the great potential of TSTs as a novel class of NNRTIs with antiviral efficacy and a good resistance profile.